The Cancer Letter

Inside information on cancer research and drug development

Guest Editorial

Congressional inaction harms federally funded oncology research and our patients:

The time for the cancer community to act is now

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

On behalf of the millions of Americans with cancer, whose very lives depend on our nation’s investment in oncology research, we ask that you join us now in urging congressional lawmakers to do the right thing: pass robust funding for the National Institutes of Health and the National Cancer Institute.

Clinical trials that test new therapeutic agents are fueled by discovery science from many sources, including laboratories funded by NIH, direct sponsorship by pharmaceutical companies, and those arising from partner research groups throughout the world. 

Although the pharmaceutical industry plays an important role in developing new drugs, clinical oncology research funded by the U.S. government remains a particularly critical path for accelerating new therapies, providing transformative benefit to patients facing cancer.  

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Howard A. "Skip" Burris, III, MD, FACP, FASCO
Chair, Association for Clinical Oncology (ASCO)
Charles D. Blanke, MD, FASCO, FAWM
Chair, SWOG Cancer Research Network
Monica M. Bertagnolli, MD, FACS, FASCO
Chair, Alliance for Clinical Trials in Oncology
Peter J. O'Dwyer, MD
Co-Chairs, ECOG-ACRIN Cancer Research Group
Mitchell D. Schnall, MD, PhD
Co-Chairs, ECOG-ACRIN Cancer Research Group
Douglas S. Hawkins, MD
Group Chair, Children’s Oncology Group
Quynh-Thu Le, MD, FACR, FASTRO
Co-Chairs, NRG Oncology
Robert S. Mannel, MD
Co-Chairs, NRG Oncology
Norman Wolmark, MD, FACS, FRCSC
Co-Chairs, NRG Oncology
Janet Dancey, MD, FRCPC
Chair, Canadian Cancer Trials Group
Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

Oncology providers, advocates form LGBTQ+ community group at ASCO with focus on research, education, equity

“When I joined ASCO in 2001, the most important thing to me was networking. I savored the opportunities to come to the annual meeting to meet and to talk with those who had led the studies that would inform standards of care, particularly in gynecologic oncology,” said Don S. Dizon. 
By Don S. Dizon, Chunkit Fung, Paula Chambers Raney, Charles Kamen and Shail Maingi
Clinical Roundup

Black patients who receive docetaxel for breast cancer experience less peripheral neuropathy than those who receive paclitaxel

Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center and the IU School of Medicine have discovered that Black patients with breast cancer who are treated with docetaxel experience less peripheral neuropathy. Their findings represent an important shift in knowledge about a patient population who’ve historically been underrepresented in breast cancer research.
Clinical Roundup

Sarclisa combination improves PFS in newly diagnosed transplant-ineligible MM in phase III trial

Data from the IMROZ phase III trial demonstrated Sarclisa (isatuximab) in combination with standard-of-care bortezomib, lenalidomide and dexamethasone followed by Sarclisa-Rd (the IMROZ regimen) significantly reduced the risk of disease progression or death by 40%, compared to VRd followed by Rd in patients with newly diagnosed multiple myeloma not eligible for transplant. 
Clinical Roundup

Enhertu demonstrated median PFS of 13.2 months in IHC 1+ or IHC 2+/ISH- metastatic breast cancer in phase III trial

Detailed positive results from the DESTINY-Breast06 phase III trial showed that Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemotherapy in patients with HR-positive, HER2-low metastatic breast cancer and the overall trial population (patients with HR-positive, HER2-low and HER2-ultralow [defined as IHC 0 with membrane staining] expression) following one or more lines of endocrine therapy. 
Byline
Howard A. "Skip" Burris, III, MD, FACP, FASCO
Chair, Association for Clinical Oncology (ASCO)
Charles D. Blanke, MD, FASCO, FAWM
Chair, SWOG Cancer Research Network
Monica M. Bertagnolli, MD, FACS, FASCO
Chair, Alliance for Clinical Trials in Oncology
Peter J. O'Dwyer, MD
Co-Chairs, ECOG-ACRIN Cancer Research Group
Mitchell D. Schnall, MD, PhD
Co-Chairs, ECOG-ACRIN Cancer Research Group
Douglas S. Hawkins, MD
Group Chair, Children’s Oncology Group
Quynh-Thu Le, MD, FACR, FASTRO
Co-Chairs, NRG Oncology
Robert S. Mannel, MD
Co-Chairs, NRG Oncology
Norman Wolmark, MD, FACS, FRCSC
Co-Chairs, NRG Oncology
Janet Dancey, MD, FRCPC
Chair, Canadian Cancer Trials Group
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account